Patent ID: 7872013

Claim:
A compound of Formula 1: or a single enantiomer, a mixture of a (+)-enantiomer and a (−)-enantiomer, a mixture of about 90% or more by weight of the (−)-enantiomer and about 10% or less by weight of the (+)-enantiomer, a mixture of about 90% or more by weight of the (+)-enantiomer and about 10% or less by weight of the (−)-enantiomer, an individual diastereomer, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, wherein: any bond represented by a dashed line and a solid line represents a bond selected from the group consisting of a single bond and a double bond, and any carbon-carbon double bond has a configuration selected from the group consisting of cis and trans; R 2 , R 3 , R 4 , R 5 , R 6 , R 8 , R 9 , R 10 , R 11 , and R 12 are independently selected from the group consisting of hydrogen, and deuterium; R 1 and R 7 are independently selected from the group consisting of hydrogen, deuterium, —CH 3 , —CDH 2 , —CD 2 H, and —CD 3 ; R 13 is selected from the group consisting of hydrogen, deuterium, —OH, and —OD; when the bond represented by a dashed line and a solid line represents a double bond, X and Y are independently selected from the group consisting of C—H, and C-D; when the bond represented by a dashed line and a solid line represents a single bond, X and Y are independently selected from the group consisting of CH 2 , CHD, and CD 2 ; Z is selected from the group consisting of C(H)OH, C(H)OD, C(D)OH, C(D)OD, and carbonyl (C═O); provided that a compound of Formula 1 contains at least one deuterium atom and that deuterium enrichment in a compound of Formula 1 is at least about 1%; and with the proviso that a compound of Formula 1 cannot be selected from the group consisting of: